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Modulation of calcium oxalate monohydrate crystallization
kinetics in vitro
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Modulation of calcium oxalate monohydrate crystallization kinetics in
vitro. The effects of several low and high molecular weight (mol wt)
compounds on the kinetics of calcium oxalate crystallization were
examined using a seeded crystal growth method in which the solubility,
the growth and the agglomeration of calcium oxalate crystals were
measured as three separate and system-independent parameters. Cit-
rate, magnesium, phosphate, pyrophosphate, chondroitinsuiphate, pen-
tosanpolysulphate and heparin were tested in a wide range of concen-
trations. The solubility of calcium oxalate crystals was increased only
by citrate and magnesium. The crystal growth was inhibited by all
compounds tested, but those with the high mol wt had the greatest
effect at low concentrations. In contrast, inhibition of crystal agglom-
eration was achieved only by the low mol wt compounds; citrate was
found to be the most potent inhibitor at concentrations likely to be
present in normal urine. The high mol wt substances, despite their
potent crystal growth inhibitory activity, had no effect on agglomera-
tion. The results show that growth and agglomeration of calcium
oxalate crystals are separate processes which are differently modulated
by various compounds. They further provide a possible explanation for
the pathogenetic role of citrate in hypocitraturic renal stone disease.
Most of the currently employed treatments of renal stone
disease are of empirical nature and as a rule aim at reducing the
supersaturation of urine with calcium oxalate. The natural
history of renal stone disease makes the evaluation of the
effective mode of action of any potential therapeutic agent a
tedious and long-term commitment. It is, therefore, important
to define the processes involved in stone formation before
engaging in such studies and to evaluate their relative impor-
tance.
Stone formation is a biological process that involves a phys-
icochemical one, crystallization. Crystallization comprises sev-
eral components, which may all be affected differently by the
urine composition. Two main aspects are recognized, a ther-
modynamic and a kinetic. The first includes the supersaturation
which results in nucleation. The second comprises the rates of
nucleation, of crystal growth and of crystal agglomeration. At
supersaturation, these processes determine whether this results
in the development of small crystals, which may be present in
normal urine [1], or in the development of renal stones. With
the recently described methods for independent measurements
of the solubility, the growth and the agglomeration of calcium
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oxalate monohydrate crystals [2—5], it has become possible to
study the biological regulation of these kinetic processes.
In the present study, we have examined how the kinetics of
calcium oxalate monohydrate crystallization are affected by low
and high mol wt compounds, some of which are naturally
occurring in the urine or are used in the treatment of nephroli-
thiasis.
Methods
The effects of additives on the crystaffization kinetics were
determined with a seeded crystal growth system which has been
described in detail before [2—4]. The solubility product is the
lowest concentration product at which growth of added,
pregrown, crystals starts to occur, that is, the equilibrium
concentration product. It is expressed as the square root of L,
VL. The crystal growth inhibition is the actual growth con-
stant in the presence of an additive, Kaith, in relation to the
growth constant without additive, Ka,c, and is expressed as a
percentage of the latter, percent G.I. Agglomeration reduces
the rate at which mineral components are taken up. It is
therefore measured in units of time ([tm]; mm). Inhibition of
agglomeration by additives increases [tm] relative to that in a
solution without additive. The mean [tm] (± SD) in control
experiments (that is, the agglomeration proper to the particular
seed used) was 58 (± 16) minutes, N = 357. Higher values
indicate inhibition of agglomeration.
The effect of a compound on agglomeration in our system was
determined by the combination of induced changes in zeta
potential, viscous binding, van der Waals forces, solid bridge
formation and other weaker forces. Shear forces which can
affect agglomeration were present equally strong in the control
experiment as in the experiment with additive, and thus did not
contribute to differences between both experiments.
The essentials of the method, in brief, are as follows. Super-
saturated solutions were prepared with initial total concentra-
tions of calcium, TCai, and oxalate, T01, of 0.372 m, and were
buffered at pH 6.00 with 7.5 m sodium dimethylarsinate. A
tracer amount of 45Ca was added and the solutions were brought
to an ionic strength of 0.15 M with sodium chloride. The
experiment, performed at 37°C, started by seeding with calcium
oxalate monohydrate crystals, in a seed concentration, s, of
0.1395 glliter. The crystals used were aged, dried and pregrown
before each experiment to ensure reproducibility in crystal
surface properties between each experiment. The crystals were
kept in suspension by shaking. At various times (t) after
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incubation, the crystals were collected on a millipore filter (0.45
) and fractional uptake, U, of 45Ca tracer into the crystals was
measured. Uptake due to exchange processes was less than 1%
in our system [2—4].
Two types of experiments were performed. In the first,
solubility of calcium oxalate monohydrate in the additive con-
taining system was measured. Growth time was fixed and initial
concentrations of calcium and oxalate were varied. In this way
the concentration product at which net growth of added crystals
started to occur with increasing concentrations of calcium and
oxalate (equilibrium product) was measured. From this value
the uptake required to reach equilibrium, Ueq, was calculated.
It should be noted that although the thermodynamic solubility
product based on equilibrium activities is contant at constant
temperature, the apparent solubility product, which is based on
concentrations, as in our system, can change considerably [3].
For example ionic strength, complexation of calcium or oxalate
by other compounds or the presence of very small crystals can
all influence the concentrations which can be retained at equi-
librium.
In a second experiment, initial concentrations of calcium and
oxalate were constant but growth time was varied. Variation of
the incubation time yielded a hyperbolic relationship between
uptake and growth time described by the following equation:
Ut_ ___
U0.
—
(t + tm)
Where U0. denoted the uptake at infinite growth time as
extrapolated from the measured growth curve and tm was the
time where uptake equals UJ2.
The thermodynamically expected U0. depended only on the
difference between initial and equilibrium concentration prod-
ucts and equaled Ueq. In practice, however, we found that the
measured U0. was always lower than the Ueq [2]. This difference
was correlated with the seed crystal concentration [2—4]. At
infinite seed concentration the U0. could be established by
extrapolation. This was called [U0.] and equals Ueq at all
supersaturations tested. This was expected, because such sys-
tems should reach equilibrium in an infinitely short time. The
difference between U0. and Ueq could be described by the
parameter [tm], the time where uptake equals [U0.]/2 according
to the following equation:
/ Ueq \ [U0.][tm] = tm
tUeq — U0.)
tm [U] — U0.
As the U0. thermodynamically could only depend on the
.tarting supersaturation, the correlation with the seed concen-
tration must be due to an influence of the seed material on the
supersaturation. This may be caused by a process which was
not regulated in our system, and which was a property of the
seed crystals used, their natural tendency to agglomerate. It
was conceivable that inside agglomerates, inclusions could
occur which were not freely accessible to the bulk solution. As
a consequence of the hindered diffusion, the crystal surface
surrounding these inclusions would 'see' a lower ambient
supersaturation than that existing in the bulk solution. Overall
for the total crystal mass, the ambient supersaturation would be
somewhat lower than could be expected on the basis of the total
calcium and oxalate concentration present. Thus, agglomera-
tion of calcium oxalate crystals could cause the decrease in
uptake as described by [tm] [4]. To validate this conclusion, we
have used an independent system, a laserflowcytometer, to
examine the agglomeration process. With the laserflowcytome-
ter actual (changes in) crystal-size distribution were measured.
The agglomeration data obtained from the laserfioweytometer
experiments agreed completely with those obtained from the
tracer experiments, thus justifying the use of [tm] as a param-
eter for agglomeration [61. The tm was a kinetic parameter
measured directly in a particular growth experiment as the time
at which uptake equaled UJ2. It was specific for the particular
supersaturation and the seed concentration used, as well as for
the agglomeration state of the particular seed. The parameter
[tm] described the specific agglomeration state of a particular
seed throughout experiments, independent from the actual
supersaturations and seed concentrations that were applied.
By differentiating equation one to the time and knowing the
effects of changes in solubility and agglomeration on the growth
rate, a final description of the kinetics of calcium oxalate
monohydrate was obtained [4]. In this equation the growth
constant Ka is characteristic for the type of seed used and was
constant under changing solution conditions. Rearrangement of
the obtained formula yielded the following equation, from
which Ka was calculated.
I [U0.] s tm /Tcai T012(I) — 1 +Ka U0. \0Tca,eq Tox.eq
The use of 45Ca tracer for following calcium uptake into the
crystals has been compared to a system where uptake of
calcium and oxalate was measured through changes in the
conductivity of the suspension [6]. Both systems were found to
produce the same growth kinetics.
The type of adsorption of inhibitors on the crystal surface
could be derived from the dose dependent changes in crystal
growth inhibition with a Langmuir type isotherm. As shown
before [7] a linear relationship between the logarithms lfl((Ka,c
Ka,inh)/Ka,inh) and ln(TIflh/M) indicated a monolayer type of
adsorption, while non-linearity pointed to other adsorption
types. Ka,c and Kainh were the growth constants in the control
experiment and in the experiment with inhibitor added, respec-
tively. T1flh denoted the total molar inhibitor concentration.
The compounds tested in this paper were four low mol wt
substances: phosphate (Na2HPO4, E. Merck, Darmstad, FRG),
citrate (Na3C6H5O7 2H20, E. Merck), magnesium (MgCl2
6H20, E. Merck), pyrophosphate (Na4P2O7. 10H20, E. Merck),
and three high mol wt substances: pentosanpolysulphate (Sigma
Chemical Co., St. Louis, Missouri, USA, mol wt 5000 daltons),
chondroitinsulphate (Sigma, mol wt 50000 daltons) and heparin
(Diosynth, Oss, The Netherlands, mol wt 16000 daltons). A
wide range of concentrations was tested, including those likely
to be present in normal urine (for the urinary constituents).
Results
Effects on solubility
Amongst the seven compounds tested, only citrate and
magnesium affected the solubility. This is shown in Figure 1.
The solubility of the calcium oxalate monohydrate crystals in
the control experiments was 0.167 mrs. Increasing citrate
(3)
(2)
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Fig. 1. The effects of citrate (S) andmagnesium (x) on the apparent
solubility of calcium oxalate monohydrate,
concentration from 0.05 m to 5.0 m increased the solubility
from 0.174 to 0.441 m. Similarly, raising magnesium concen-
tration from 0.5 m to 10.0 m increased solubility from 0.167
to 0.350 m. Phosphate in concentrations of 0.3 to 30 mM
increased solubility from 0.167 to 0.184 mrvi only. Pyrophos-
phate (1 to 100 sM), pentosanpolysulphate (0.1 to 100 LM),
Chondroitinsulfate (0.05 to 10.0 M) and heparin (0.02 to 10.0
sM) were without effect.
Effects on crystal growth
As shown in Figure 2, all of the tested substances inhibited
crystal growth. A 50% inhibition of crystal growth was exerted
approximately by: 20 m phosphate, 7 mri Mg, 0.4 m citrate,
20 M pyrophosphate, 2 /LM pentosanpolysulphate, 1.0 sM
chondroitinsulphate and 0.03 jsM heparin, respectively. Thus,
the high mol wt substances inhibited crystal growth at low
concentrations.
The Langmuir isotherm, relating lfl((Ka,cKa,jnh)/Ka,inh) with
ln(T1flh/M) was linear in the cases of the high mol wt substances,
pentosanpolysulphate (slope 0.24), chondroitinsuiphate (slope
0.6) and heparin (slope 0.24), and in the case of pyrophosphate
(slope 1). This indicated a monolayer type of adsorption. Their
mode of action could thus involve a simple surface-kink poi-
soning, the macromolecules in view of their low effective
concentrations having a preference for the growth sites. The
Langmuir isotherms for phosphate, citrate and magnesium were
not linear, indicating perhaps a different adsorption behavior.
Effects on agglomeration
The results in Figure 3 indicate that citrate is a potent
inhibitor of agglomeration even at low concentrations. Magne-
sium inhibits agglomeration only slightly, and only at high
concentrations, while phosphate had no effects. Pyrophosphate
had no effect at low concentrations, but at very high concen-
trations it inhibited agglomeration strongly. Among the macro-
molecules only chondroitinsulphate had a slight inhibitory
effect, and pentosanpolysulphate and heparin had none.
Discussion
It is generally thought that supersaturation of urine is the
prime element responsible for calcium oxalate stone formation.
Consequently, management and prevention of renal stone dis-
ease have been focused on lowering the urinary calcium and
oxalate concentrations. These concentrations are, however,
normal in the urines of a number of stone formers and the
calcium oxalate product is not different from that in normal
urine. It may be that in those patients the effective concentra-
tion product is increased by diminished excretion of substances
which complex calcium or oxalate. From the present solubility
measurements and as generally assumed, it would appear that
reduced citrate and magnesium could have this effect. On the
other hand, it is unlikely that nucleation alone can be respon-
sible for the renal stone formation, as crystalluria is as frequent
in normal urines as in stone former urines [1]. In addition,
particles must reach a certain size in order to remain in the
urinary tract and form a stone, while small particles can be
excreted with no consequences. Therefore, other processes
affecting the size of particles must be involved. Two separate
physicochemical processes govern particle size, namely growth
and agglomeration of calcium oxalate crystals, and these were
here independently assessed.
Low concentrations of high mol wt substances were found to
inhibit the growth of crystals, but it appeared that they had
hardly any inhibitory effect on their agglomeration. On the
other hand, the low mol wt compounds, which only inhibited
growth when concentrations were high, exerted a strong inhib-
itory action on the agglomeration. Thus, effects of different
compounds on growth and agglomeration of calcium oxalate
monohydrate crystals were not unidirectional (they could even
be opposing [6, 7]). Crystal growth and crystal agglomeration,
therefore, are distinct processes which can be dissociated.
This is in agreement with our previous studies, where it was
found that urines from stone formers with frequent recurrence
and from healthy persons, diluted 1:5, inhibited crystal growth
to the same extent, but the difference found in their ability to
inhibit crystal agglomeration was striking [8, 9]. Crystal agglom-
eration is, therefore, a separate central element in calcium
oxalate stone formation. There is additional evidence in support
of that premise. For example, though total crystalluria is the
same in healthy subjects and in stone formers, the percentage of
large particles, especially agglomerates, is higher in the stone
former group [1]. In recurrent stone formers, there is close
correlation between the number of particles (mainly agglomer-
ates) larger than 12 x excreted and the number of stone
episodes per year [1]. It has also been calculated [10] that the
influence of crystal growth on the size of a single crystal during
the short transit time of urine in the urinary tract is not large
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Fig. 2. Crystal growth inhibition, % G.I., was
achieved by all substances tested. Symbols
are: (0) phosphate 0.3—30 mM; (X) magnesium
0.5—10 mM; (•) citrate 0.05—2.5 mM; (0)
10-2 pyrophosphate 1—100 M; (A) pentosan-polysulfate 1—100 .tM; (U) chondroitinsulfate
0.1—10 iLM; () heparin 0.05—10 M.
____________________ Fig. 3. Effects on crystal agglomeration, high
values of[tm] indicate inhibition relative to
the control situation. Symbols are: (0)
phosphate 0.3—30 mM; (X) magnesium 0.5—25
mM; (•) 0.05—25 mM; (0) pyrophosphate
-
1—100 ILM; (A) pentosanpolysulfate 1—100 M;i0- 10_6 iO 10 i- 102 10 ' (U)chondroitinsulfate0.l—1OuM;(A)heparin
Tflh, M 0.05—10 J.M.
enough to cause the crystal to remain in the system. It has,
therefore, been proposed that crystal retention, increasing
transit times, is necessary (fixed particle mechanism) [10, 11].
The rapidity, however, with which crystal agglomeration is
accomplished may suffice to explain why the particles may
become large enough for retention. Large agglomerates have a
greater chance to stick to walls or to be retained in dead
volumes sites, than single crystals. Finally, the average renal
stone has an agglomerate structure indeed, rather than consist-
ing of a single large crystal [12—151.
Among the several candidates we tested, magnesium, citrate
and pyrophosphate were the only ones found with an inhibitory
effect on agglomeration. These three have all previously been
implicated as acting on "growth and agglomeration" [16, 171. It
is now evident that here mainly the agglomeration is involved.
Direct comparison of our data with other previously published
material is not possible. For the measurement of the crystalli-
zation processes, well designed systems must be used. Both
experimental parameters (ionic strength, pH, seed type, seed
concentration) and physicochemical processes (solubility,
growth, agglomeration) determine measured growth rates and
crystal size distributions. It is therefore important that all these
must be precisely defined and accounted for before any attempt
at comparing data obtained by various methods is made.
In the present study citrate was found to be the most potent
inhibitor of calcium oxalate crystal agglomeration at concentra-
tions similar to those found in normal urine. At higher concen-
trations, representing citrate/calcium ratios which can be found
under no physiological or pathological condition, this effect was
not sustained. Of course, these in vitro data cannot directly be
extrapolated to the more complex urinary conditions, where
several substances which may modulate the effect on calcium
oxalate crystallization are also present. However, these results
conform to our previous findings in studies with urines from
stone formers. The urines from these hypocitraturic patients,
which had lost their ability to inhibit crystal agglomeration,
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regained this ability after the citrate content was increased [8, 6.
181.
It is, therefore, clear that growth and agglomeration of
calcium oxalate crystals are differently modulated and must not
be considered collectively. In this way the physicochemical
basis of treatments aiming at inhibiting crystallization of cal-
cium oxalate can be better defined and more rational ways of
preventing renal stone formation can be developed.
Acknowledgments
The support of The Dutch Kidney Foundation is gratefully acknowl-
edged. We thank Mr. I. Que for technical assistance and Mrs. F.
Boegborn for her secretarial assistance.
Reprint requests to Dr. S.E. Papapoulos, Clinical Investigation Unit,
Department of Endocrinology, Geb. 1, C4-R, University Hospital,
Rjjnsburgerweg 10, 2333 AA Leiden, The Netherlands.
References
1. ROBERTSON WG: Saturation-inhibition as a measure of the risk of
calcium oxalate stone formation, in Idiopathic urinary bladder
stone disease, edited by R VAN REEN, Fogarty mt. Cent. Proc.
Wash. D.C., U.S. Gov. Printing Office, 1977, vol. 37, pp. 55—71
2. WILL EJ, BUVOET OLM, BLOMEN LJMJ, VD LINDEN H: Growth
kinetics of calcium oxalate monohydrate 1. J Cryst Growth 64:297—
305, 1983
3. BLOMEN LJMJ, WILL EJ, BIJVOET OLM, VD LINDEN H: Growth
kinetics ofcalcium oxalate monohydrate 2. J Cryst Growth 64:306—
315, 1983
4. BUVOET OLM, BLOMEN LJMJ, WILL EJ, VD LINDEN H: Growth
kinetics of calcium oxalate monohydrate 3. J Cryst Growth 64:316—
325, 1983
5. BLOMEN LJMJ, BIJVOET OLM, VD LINDEN H: Die Loslichkeit von
Calcium Oxalat Monohydrat. Fortschr Urol u Nephrol 17:159—166,
1981
BLOMEN LJMJ: Growth and agglomeration of calcium oxalate
monohydrate. Thesis, Leiden University, Leiden 1982
K0K DJ, BLOMEN LJMJ, WESTBROEK P. BUVOET OLM: Polysac-
charide from coccoliths (CaCO3 biomineral). Eur J Biochem 158:
167—172, 1986
8. KOK DJ, PAPAPOULOS SE, BIJVOET OLM: Excessive crystal ag-
glomeration with low citrate excretion in recurrent stone formers,
Lancet i:1056—l058, 1986
9. Koi DJ, PAPAPOULOS SE, BUVOET OLM: Defective or absent
inhibition of agglomeration in the presence of normal inhibition of
crystal growth in stone formers with a high recurrence rate.
Fortschr Urol u Nephrol 23:19—23, 1985
10. FINLAYSONB: Where and how does urinary stone disease start?, in
Idiopathic Urinary Bladder Stone Disease, edited by R. VAN REEN
Fogarty mt. Cent. Proc. Wash. D.C., U.S. Gov. Printing Office,
vol. 37, 1977, pp. 7—31
11. BURNS JR, FINLAYSON B, GAUTHIER J: Calcium oxalate retention
in subjects with crystalluria, in Urinary Stone, edited by RYALL
RL, BROCKS J, MARSHALL yR. FINLAYSON B, Churchill Living-
stone, Melbourne, 1984, p. 253
12. IWATA H, NIsHlo S, WAKATSUIU A, OcHI K, TAKEUCHI M:
Architecture of calcium oxalate monohydrate urinary calculi. J
Urol 133:334—338, 1985
13. IsMAIL. SI, TowAsH! R: Size distribution characteristics of mineral
phase in renal stones. J Pharmacol Sci 69:829—833, 1980
14. RODGERS AL: Common ultrastructural features in human calculi.
Micron Microscopica Acta l4(3):2l9—224, 1983
15. BLOMEN LJMJ: Anwendung der Rastenelektronen mikroskopie bei
der Urolithiasis, 2 Harnsteinsymposium CSSR-DDR. Wissensch
Beitr der Friedrich Schiller Univ Jena: 67—74, 1982
16. RYALL RL, HARNETT RM, MARSHALL VR: The effect of urine,
pyrophosphate, citrate, magnesium and glycosaminoglycans on the
growth and aggregation of calcium oxalate crystals in vitro. Clin
Chi,nActa 112:349—356, 1981
17. AZOURY R, GARSIDE J, ROBERTSON WG: Calcium oxalate precip-
itation in a flow system. J Urol 136:150—153, 1986
18. KOK Di, PAPAPOULOS SE, BIJVOET OLM: A physicochemical
explanation for the role of citrate in recurrent Stone disease.
Fortschr Urol u Nep/irol 25:284—288, 1986
